Teva Pharmaceuticals and Perrigo Company Announce the U.S. Launch of Generic Temozolomide

  Teva Pharmaceuticals and Perrigo Company Announce the U.S. Launch of Generic
  Temozolomide

Business Wire

JERUSALEM & ALLEGAN, Mich. -- August 12, 2013

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Perrigo Company (NYSE:
PRGO;TASE) today announced the launch of the generic equivalent to Temodar®
(temozolomide). Teva will manufacture, market and distribute the product in
the U.S. and both companies will equally share in the cost and profitability
of the product in the U.S. Teva was first to file, making the product eligible
for 180 days of marketing exclusivity.

This product is the generic equivalent to Temodar® (temozolomide), indicated
for the treatment of adult patients with newly diagnosed glioblastoma
multiforme concomitantly with radiotherapy and then as maintenance treatment
and refractory anaplastic astrocytoma patients who have experienced disease
progression on a drug regimen containing nitrosourea and procarbazine.
Temodar® had annual sales of approximately $423 million in the United States,
according to IMS data as of December 31, 2012. The launch of this product
provides a quality alternative, making cancer therapy more cost effective for
patients who suffer from this devastating cancer.

Perrigo’s Chairman, President and CEO Joseph C. Papa stated, “This
first-to-file launch with our partner Teva is another example of our focus to
manufacture complex API’s. We are pleased to offer this important product to
patients in the United States.”

“We are pleased to partner with Perrigo to offer patients a high-quality, less
expensive alternative of this important medicine. This launch demonstrates
Teva’s commitment to continue to pursue first-to-market opportunities and
enhance the value of our portfolio by concentrating on high-margin, low
competition markets,” stated Allan Oberman, President and CEO of Teva Americas
Generics.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global
pharmaceutical company, committed to increasing access to high-quality
healthcare by developing, producing and marketing affordable generic drugs as
well as innovative and specialty pharmaceuticals and active pharmaceutical
ingredients. Headquartered in Israel, Teva is the world's leading generic drug
maker, with a global product portfolio of more than 1,000 molecules and a
direct presence in about 60 countries. Teva's branded businesses focus on CNS,
oncology, pain, respiratory and women's health therapeutic areas as well as
biologics. Teva currently employs approximately 46,000 people around the world
and reached $20.3 billion in net revenues in 2012.

About Perrigo

From its beginnings as a packager of generic home remedies in 1887, Allegan,
Michigan-based Perrigo Company has grown to become a leading global provider
of quality, affordable healthcare products. Perrigo develops, manufactures and
distributes over-the-counter (OTC) and generic prescription (Rx)
pharmaceuticals, infant formulas, nutritional products, animal health, dietary
supplements and active pharmaceutical ingredients (API). The Company is the
world’s largest manufacturer of OTC pharmaceutical products for the store
brand market. The Company’s primary markets and locations of logistics
operations have evolved over the years to include the United States, Israel,
Mexico, the United Kingdom, India, China and Australia. Visit Perrigo on the
Internet (http://www.perrigo.com).

Teva's Safe Harbor Statement under the U. S. Private Securities Litigation
Reform Act of 1995:

This release contains forward-looking statements, which express the current
beliefs and expectations of management. Such statements are based on
management’s current beliefs and expectations and involve a number of known
and unknown risks and uncertainties that could cause our future results,
performance or achievements to differ significantly from the results,
performance or achievements expressed or implied by such forward-looking
statements. Important factors that could cause or contribute to such
differences include risks relating to: our ability to develop and
commercialize additional pharmaceutical products, including our ability to
develop, manufacture, market and sell biopharmaceutical products, competition
for our innovative products, especially Copaxone® (including competition from
innovative orally-administered alternatives, as well as from potential
purported generic equivalents), competition for our generic products
(including from other pharmaceutical companies and as a result of increased
governmental pricing pressures), competition for our specialty pharmaceutical
businesses, our ability to achieve expected results through our specialty,
including innovative, R&D efforts, the effectiveness of our patents and other
protections for innovative products, decreasing opportunities to obtain U.S.
market exclusivity for significant new generic products, our ability to
identify, consummate and successfully integrate acquisitions, the effects of
increased leverage as a result of recent acquisitions, the extent to which any
manufacturing or quality control problems damage our reputation for high
quality production and require costly remediation, our potential exposure to
product liability claims to the extent not covered by insurance, increased
government scrutiny in both the U.S. and Europe of our agreements with brand
companies, potential liability for sales of generic products prior to a final
resolution of outstanding patent litigation. our exposure to currency
fluctuations and restrictions as well as credit risks, the effects of reforms
in healthcare regulation and pharmaceutical pricing and reimbursement, any
failures to comply with complex Medicare and Medicaid reporting and payment
obligations, governmental investigations into sales and marketing practices
(particularly for our specialty pharmaceutical products), uncertainties
surrounding the legislative and regulatory pathways for the registration and
approval of biotechnology-based products, adverse effects of political or
economical instability, corruption, major hostilities or acts of terrorism on
our significant worldwide operations, interruptions in our supply chain or
problems with our information technology systems that adversely affect our
complex manufacturing processes, any failure to retain key personnel or to
attract additional executive and managerial talent, the impact of continuing
consolidation of our distributors and customers, variations in patent laws
that may adversely affect our ability to manufacture our products in the most
efficient manner, potentially significant impairments of intangible assets and
goodwill, potential increases in tax liabilities, the termination or
expiration of governmental programs or tax benefits, environmental risks and
other factors that are discussed in our Annual Report on Form 20-F for the
year ended December 31, 2012 and in our other filings with the U.S. Securities
and Exchange Commission. Forward-looking statements speak only as of the date
on which they are made and the Company undertakes no obligation to update or
revise any forward-looking statement, whether as a result of new information,
future events or otherwise.

Perrigo’s Safe Harbor Statement: Certain statements in this press release are
forward-looking statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, and are subject to the safe harbor created
thereby. These statements relate to future events or the Company’s future
financial performance and involve known and unknown risks, uncertainties and
other factors that may cause the actual results, levels of activity,
performance or achievements of the Company or its industry to be materially
different from those expressed or implied by any forward-looking statements.
In some cases, forward-looking statements can be identified by terminology
such as “may,” “will,” “could,” “would,” “should,” “expect,” “plan,”
“anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential” or other
comparable terminology. The Company has based these forward-looking statements
on its current expectations, assumptions, estimates and projections. While the
Company believes these expectations, assumptions, estimates and projections
are reasonable, such forward-looking statements are only predictions and
involve known and unknown risks and uncertainties, many of which are beyond
the Company’s control. These and other important factors, including those
discussed under “Risk Factors” in the Company’s Form 10-K for the year ended
June 30, 2012, as well as the Company’s subsequent filings with the Securities
and Exchange Commission, may cause actual results, performance or achievements
to differ materially from those expressed or implied by these forward-looking
statements. The forward-looking statements in this press release are made only
as of the date hereof, and unless otherwise required by applicable securities
laws, the Company disclaims any intention or obligation to update or revise
any forward-looking statements, whether as a result of new information, future
events or otherwise.

Contact:

Teva
IR:
Kevin C. Mannix, 215-591-8912
United States
or
Ran Meir, 215-591-3033
United States
or
Tomer Amitai, 972 (3) 926-7656
Israel
or
PR:
Iris Beck Codner,  972 (3) 926-7246
Israel
or
Denise Bradley, 215-591-8974
United States
or
Perrigo
IR:
Arthur J. Shannon,  269-686-1709
ajshannon@perrigo.com
or
Bradley Joseph,  269-686-3373
bradley.joseph@perrigo.com
 
Press spacebar to pause and continue. Press esc to stop.